Sanofi announces that it has received $2.1 billion from OWS for 100 million doses of the experimental coronavirus vaccine that it is developing in partnership with GlaxcoSmithKline (GSK). The deal has raised concerns since the head of OWS, Moncef Slaoui, is a former executive of GSK who owned nearly $10 million in stock in May 2020; he also has stock in other companies that are developing vaccines. Source